Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

Axitinib demonstrated clinical activity and safety in treatment-naïve Japanese patients with metastatic renal cell carcinoma. Multivariate analyses identified potential predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma.

[1]  K. Yamashita,et al.  Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[2]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[3]  E. Jonasch,et al.  Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. , 2013, The Lancet. Oncology.

[4]  Hyo Song Kim,et al.  Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients , 2013, Cancer Chemotherapy and Pharmacology.

[5]  M. Gore,et al.  Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma , 2013, British Journal of Cancer.

[6]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[7]  R. Motzer,et al.  Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis , 2013, Journal of clinical pharmacology.

[8]  H. Akaza,et al.  Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial , 2013, Japanese journal of clinical oncology.

[9]  T. Habuchi,et al.  Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma , 2013, Anti-cancer drugs.

[10]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[11]  H. Akaza,et al.  Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. , 2011, European journal of cancer.

[12]  T. Mukohara,et al.  Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients , 2011, Investigational New Drugs.

[13]  T. Miki,et al.  Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. , 2010, Japanese journal of clinical oncology.

[14]  T. Nishida,et al.  Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate , 2010, Investigational New Drugs.

[15]  Dae-Ho Lee,et al.  The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. , 2010, Japanese journal of clinical oncology.

[16]  H. Lee,et al.  Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience , 2010, Korean journal of urology.

[17]  T. Mukohara,et al.  Effect of axitinib (AG‐013736) on fatigue, thyroid‐stimulating hormone, and biomarkers: A phase I study in Japanese patients , 2010, Cancer Science.

[18]  T. Miki,et al.  A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. , 2010, Japanese journal of clinical oncology.

[19]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  X. Yao,et al.  Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study , 2009, BMC Cancer.

[22]  U. Kuruganti,et al.  Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers , 2009, Cancer Chemotherapy and Pharmacology.

[23]  Hyo Song Kim,et al.  Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.

[24]  E. Small,et al.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[26]  H. Mukai,et al.  Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors , 2008, Cancer science.

[27]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[28]  H. Akaza,et al.  Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. , 2007, Japanese journal of clinical oncology.

[29]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[30]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[31]  R. Herbst,et al.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.